Loading company filing…
Find a company. Follow its revenue through costs and profit.
Coverage includes separate ticker and security records; counts are not unique companies.
Sankey diagram of Cardinal Health, Inc.. A complete text table follows the diagram.
Pharmaceutical distribution supplies the profit base, Medical products struggle for margin, and at-Home, Nuclear and OptiFreight grow around the core
Swipe to explore
The diagram uses reported segment revenue and profit. Pharmaceutical cost includes the large pass-through acquisition cost of drugs, which explains its 1.4% segment margin. Corporate includes acquisition compensation, amortization, impairment, litigation, restructuring, and central costs; the filing's $956M non-GAAP operating earnings are disclosed only in annotations.
Labels and narrative explain the filing. A category marked “arithmetic bridge” or “residual” is calculated from reported totals, rather than a separately reported line.
| Category | Stage | Value | Notes |
|---|---|---|---|
| Pharmaceutical & Specialty | 1 | $56.1B | Drug distribution and specialty services; +11% |
| Global Medical Products | 1 | $3.1B | Medical products and distribution; flat |
| Nuclear & Precision Health | 1 | $478M | Radiopharmaceutical network; +19% |
| at-Home Solutions | 1 | $1.1B | Home medical supplies; +38% |
| OptiFreight Logistics | 1 | $100M | Healthcare freight optimization; +19% |
| Specialty services portfolio | 2 | $1.7B | Three faster-growing adjacencies; +31% |
| Pharma segment profit | 3 | $784M | 1.4% margin; +18% |
| Drug acquisition & operating cost | 3 | $55.3B | High-volume pharmaceutical pass-through |
| Medical segment profit | 3 | $25M | 0.8% margin; down 36% |
| Medical products & operating cost | 3 | $3.1B | Manufacturing, sourcing and distribution |
| Specialty services profit | 3 | $179M | 10.5% margin; +34% |
| Specialty service delivery cost | 3 | $1.5B | Clinical, logistics and home-delivery operations |
| Portfolio segment profit | 4 | $988M | Pharma supplies 79% of the pool |
| GAAP operating earnings | 5 | $509M | Reported result after corporate items |
| Corporate & acquisition burden | 5 | $479M | Central costs and portfolio reshaping |
| From | To | Value |
|---|---|---|
| Nuclear & Precision Health | Specialty services portfolio | $478M |
| at-Home Solutions | Specialty services portfolio | $1.1B |
| OptiFreight Logistics | Specialty services portfolio | $100M |
| Pharmaceutical & Specialty | Pharma segment profit | $784M |
| Pharmaceutical & Specialty | Drug acquisition & operating cost | $55.3B |
| Global Medical Products | Medical segment profit | $25M |
| Global Medical Products | Medical products & operating cost | $3.1B |
| Specialty services portfolio | Specialty services profit | $179M |
| Specialty services portfolio | Specialty service delivery cost | $1.5B |
| Pharma segment profit | Portfolio segment profit | $784M |
| Medical segment profit | Portfolio segment profit | $25M |
| Specialty services profit | Portfolio segment profit | $179M |
| Portfolio segment profit | GAAP operating earnings | $509M |
| Portfolio segment profit | Corporate & acquisition burden | $479M |